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Hepcidin-guided screen-and-treat interventions against 
iron-deficiency anaemia in pregnancy: a randomised 
controlled trial in The Gambia
Amat Bah, Abdul Khalie Muhammad, Rita Wegmuller, Hans Verhoef, Morgan M Goheen, Saikou Sanyang, Ebrima Danso, Ebrima A Sise, 
Sant-Rayn Pasricha, Andrew E Armitage, Hal Drakesmith, James H Cross, Sophie E Moore, Carla Cerami, Andrew M Prentice
Summary
Background WHO recommends daily iron supplementation for pregnant women, but adherence is poor because of 
side-effects, effectiveness is low, and there are concerns about possible harm. The iron-regulatory hormone hepcidin 
can signal when an individual is ready-and-safe to receive iron. We tested whether a hepcidin-guided screen-and-treat 
approach to combat iron-deficiency anaemia could achieve equivalent efficacy to universal administration, but with 
lower exposure to iron.
Methods We did a three-arm, randomised, double-blind, non-inferiority trial in 19 rural communities in the Jarra West 
and Kiang East districts of The Gambia. Eligible participants were pregnant women aged 18–45 years at between 
14 weeks and 22 weeks of gestation. We randomly allocated women to either WHO’s recommended regimen 
(ie, a daily UN University, UNICEF, and WHO international multiple-micronutrient preparation [UNIMMAP] 
containing 60 mg iron), a 60 mg screen-and-treat approach (ie, daily UNIMMAP containing 60 mg iron for 7 days if 
weekly hepcidin was <2·5 µg/L or UNIMMAP without iron if hepcidin was ≥2·5 µg/L), or a 30 mg screen-and-treat 
approach (ie, daily UNIMMAP containing 30 mg iron for 7 days if weekly hepcidin was <2·5 µg/L or UNIMMAP 
without iron if hepcidin was ≥2·5 µg/L). We used a block design stratified by amount of haemoglobin at enrolment 
(above and below the median amount of haemoglobin on every enrolment day) and stage of gestation (14–18 weeks vs 
19–22 weeks). Participants and investigators were unaware of the random allocation. The primary outcome was the 
amount of haemoglobin at day 84 and was measured as the difference in haemoglobin in each screen-and-treat group 
compared with WHO’s recommended regimen; the non-inferiority margin was set at –5·0 g/L. The primary outcome 
was assessed in the per-protocol population, which comprised all women who completed the study. This trial is 
registered with the ISRCTN registry, number ISRCTN21955180.
Findings Between June 16, 2014, and March 3, 2016, 498 participants were randomised, of whom 167 were allocated to 
WHO’s recommended regimen, 166 were allocated to the 60 mg per day screen-and-treat approach, and 165 were 
allocated to the 30 mg per day screen-and-treat approach. 78 participants were withdrawn or lost to follow-up during the 
study; thus, the per-protocol population comprised 140 women assigned to WHO’s recommended regimen, 133 allocated 
to the 60 mg screen-and-treat approach, and 147 allocated to the 30 mg screen-and-treat approach. The screen-and-treat 
approaches did not exceed the non-inferiority margin. Compared with WHO’s recommended regimen, the difference 
in the amount of haemoglobin at day 84 was –2·2 g/L (95% CI –4·6 to 0·1) with the 60 mg screen-and-treat approach 
and –2·7 g/L (–5·0 to –0·5) with the 30 mg screen-and-treat approach. Adherence, reported side-effects, and adverse 
events were similar between the three groups. The most frequent side-effect was stomachache, which was similar in 
the 60 mg screen-and-treat group (82 cases per 1906 person-weeks) and with WHO’s recommended regimen (81 cases 
per 1974 person-weeks; effect 1·0, 95% CI 0·7 to 1·6); in the 30 mg screen-and-treat group the frequency of 
stomachache was slightly lower than with WHO’s recommended regimen (58 cases per 2009 person-weeks; effect 
0·7, 95% CI 0·5 to 1·1). No participants died during the study.
Interpretation The hepcidin-guided screen-and-treat approaches had no advantages over WHO’s recommended 
regimen in terms of adherence, side-effects, or safety outcomes. Our results suggest that the current WHO policy for 
iron administration to pregnant women should remain unchanged while more effective approaches continue to be 
sought.
Funding Bill & Melinda Gates Foundation and the UK Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Iron deficiency and associated anaemia is the most 
prevalent micronutrient deficiency worldwide, affecting 
an estimated 1·24 billion people.1 It is the leading cause 
of years lived with disability in most of sub-Saharan 
Africa and many parts of Asia.1 WHO recommends 
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universal daily iron and folic acid supplementation in 
pregnancy,2 based on evidence from a Cochrane review 
that it provides maternal and neonatal health benefits3 
such as prevention of maternal anaemia, puerperal 
sepsis, low birthweight, and preterm birth. The reco- 
mmended daily dose is 30–60 mg elemental iron, with a 
preferred dose of 60 mg per day in countries where 
anaemia prevalence exceeds 40%.2 In low-income and 
middle-income countries (LMICs), iron and folic acid 
supplementation has great benefits for iron-deficient 
women4 and is increasingly being combined in multiple 
micronutrient formulations.5 However, even when 
supplements are made available, implementation of a 
daily supplementation policy in LMICs is highly variable 
and adherence to a daily regimen is poor,4–7 attributable in 
large part to common gastrointestinal side-effects such as 
constipation, nausea, vomiting, black stools, and epigastric 
discomfort.8,9 WHO subsequently recommended inter- 
mittent supplementation if daily iron caused side-
effects.10,11 Concerns have also been reported that iron 
supplementation can predispose to haemoconcentration3 
and gestational diabetes.12 In low-income settings, an 
additional possibility is that iron supplementation 
might increase gastrointestinal and other infections,4 
particularly malaria. Anaemia and low iron status are 
associated with protection against falciparum malaria in 
pregnant women,13,14 and there are clear pathways by 
which iron administration abrogates this protection.15 
Thus, lowering the dose of supplemental iron could be 
beneficial if it could be achieved without compromising 
efficacy.
We reasoned that hepcidin, the hepatic iron-
regulatory peptide that acts as a master regulator of 
iron metabolism, could signal when women are 
ready-and-safe to receive iron and, hence, could form 
the basis of a screen-and-treat iron and folic acid 
supplementation regimen. Hepcidin is the homoeo-
static regulator of body iron absorption, distribution, 
and metabolism.16 Circulating hepcidin is suppressed 
during iron deficiency, anaemia, and increased erythro-
poiesis, and amounts of hepcidin are increased by high 
levels of iron in serum and the liver and during 
infection and inflammation.17 By integrating these 
competing signals, a low amount of hepcidin indicates 
when the body is iron-deficient18,19 and will efficiently 
absorb iron.20 Conversely, raised amounts of hepcidin 
would block duodenal iron absorption thereby ren-
dering supplementation ineffective and exposing the 
gut microbiota to unnecessary iron that could cause 
dysbiosis and side-effects.21
We postulated that a hepcidin-guided screen-and-
treat approach to iron supplementation would be 
non-inferior to WHO’s recommended universal daily 
supplemen tation. Moreover, by lowering the total 
exposure to iron, we thought that this screen-and-treat 
approach might lead to better adherence and an 
improved side-effect and safety profile. Therefore, we 
designed the Hepcidin and Anaemia in Pregnancy 
(HAPn) study, a 12-week ran domised, double-blind, 
non-inferiority trial in pregnant women from The 
Gambia, to assess these ideas.
Methods
Study design
Full details of the study design are in the appendix (pp 1, 2) 
and the published trial protocol.22 The HAPn study 
Research in context
Evidence before this study
Based on regularly updated meta-analyses, WHO recommends 
that pregnant women should take supplements containing 
30–60 mg elemental iron and 400 μg folic acid daily to 
prevent maternal anaemia, puerperal sepsis, low birthweight, 
and preterm birth. If daily supplementation is not acceptable 
because of side-effects, weekly supplementation with 120 mg 
iron and 2800 μg folic acid is a suitable alternative in settings 
where the prevalence of anaemia is less than 20%. Side-effects 
are frequently reported, however, and contribute to poor 
adherence. An additional concern is that iron might 
predispose to gestational diabetes, pre-eclampsia, and 
infections. We reasoned that a screen-and-treat approach to 
combat anaemia in pregnancy would be advantageous if it 
could achieve efficacy that was equivalent to or better than 
that achieved by WHO’s recommendations, but at a lower 
overall dose of iron and with fewer side-effects.
Added value of this study
We did a double-blind randomised trial to test two 
hepcidin-guided screen-and-treat approaches against the 
standard-of-care 60 mg per day regimen. We calculated a 
threshold for the iron-regulatory hormone hepcidin that would 
indicate whether a participant was ready-and-safe to receive 
iron. Our study is, to the best of our knowledge, the first to 
assess hepcidin-guided antenatal iron supplementation. 
The weekly screen-and-treat approach was non-inferior to the 
standard-of-care regimen. No evidence was found that the 
screen-and-treat approach was safer with respect to adverse 
events or ex-vivo tests of Plasmodium falciparum growth in 
red blood cells or sentinel bacterial growth in plasma.
Implications of all the available evidence
We were unable to show any clear advantages of a 
hepcidin-guided screen-and-treat approach to maternal iron 
supplementation over current WHO recommendations. 
These data and other available evidence suggest that efforts 
should be directed towards developing low-cost iron 
supplements with better side-effect profiles to help overcome 
poor adherence that currently undermines antenatal 
iron-supplementation programmes.
See Online for appendix
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is a randomised, double-blind, proof-of-concept, non-
inferiority trial to assess WHO’s recommended daily 
iron regimen with two screen-and-treat approaches. We 
did the study in 19 rural communities in the Jarra West 
and Kiang East districts of The Gambia. In these 
locations, anaemia is common and malaria endemicity is 
low, heterogeneous, and seasonal.
Nurse midwives and fieldworkers identified and 
screened pregnant women at their first antenatal care 
visits (day 0) at two health facilities (Soma Health Centre, 
Soma Town, Jarra West; and Kaiaf Health Centre, 
Kaiaf Town, Kiang East), obtained informed consent, 
and gathered demographic information. Women aged 
18–45 years were eligible for randomisation if gestational 
age was 14–22 weeks. Gestational age was assessed by 
either self-reported first date of last menstrual period or, 
if the woman could not recall this information, by fundal 
height. We excluded women if they were unlikely to 
remain in the area for the duration of the study, had 
severe anaemia (haemoglobin concentration <70 g/L), 
had a serious illness, had chronic disease, or self-reported 
a history of previous pregnancy complications (eg, 
repeated miscarriage or abortions, pre-eclampsia or 
eclampsia). At enrolment (day 0), women were provided 
with long-lasting insecticide-treated bed nets. Any 
woman found to have a concentration of haemoglobin 
lower than 70 g/L during the trial was treated as per the 
Gambian national protocol.
The trial was approved by the Medical Research Council 
(MRC) Unit The Gambia Scientific Coordinating Com-
mittee (SCC), Joint Gambia Government MRC ethics 
committee (SCC 1357, amendments L2014.56v2), and the 
London School of Hygiene & Tropical Medicine (LSHTM) 
ethics committee (no 7168). The trial was overseen by a 
data safety monitoring board, trial steering committee, 
and trial monitor, and it was done according to Good 
Clinical Practice standards supervised by the MRC Unit 
The Gambia at LSHTM (MRCG@LSHTM) Clinical 
Trials Office. All participants gave written informed 
consent.
Randomisation and masking
At screening (day 0), eligible women were randomly 
allocated (1:1:1) using computer-generated numbers to one 
of three intervention arms: (1) WHO’s recommended 
regimen of daily supplementation with UN University, 
UNICEF, and WHO international multiple micronutrient 
capsules (UNIMMAP) containing 60 mg iron as ferrous 
fumarate (the reference group); (2) weekly screening of 
plasma hepcidin for 12 weeks, every time succeeded by 
either daily supplementation for 7 days with UNIMMAP 
containing 60 mg iron if the concentration in plasma of 
hepcidin was less than 2·5 µg/L or daily supplementation 
for 7 days with UNIMMAP containing no iron if hepcidin 
levels were 2·5 µg/L or higher (the 60 mg screen-and-
treat group); or (3) screen-and-treat supplementation as 
described for the 60 mg screen-and-treat group but with 
UNIMMAP containing 30 mg iron (the 30 mg screen-and-
treat group). Calculation of the hepcidin threshold of less 
than 2·5 µg/L to define ready-and-safe to receive iron has 
been described previously.19 Randomisation was based 
on a permuted block design (block size of nine) with 
stratification by haemoglobin (above and below the median 
concentration of haemoglobin of the respective enrolment 
day) and gestational age (14–18 weeks or 19–22 weeks), to 
account for natural differences in haematological and iron 
status. Participants and the research team (except for the 
data manager) were unaware of group allocation and 
supplementation type throughout the fieldwork. Supple-
ments were prepacked weekly by the field coordinator 
using computer-generated lists accounting for each 
participant’s preceding hepcidin value. UNIMMAP was 
produced in three variants containing 60 mg, 30 mg, or 
no iron (DSM Nutritional Products, Johannesburg, South 
Africa) as identical gelatine capsules, packed in tubs under 
Good Manu facturing Practice conditions. All formulations 
also contained 400 µg folic acid and 13 other micronu-
trients (appendix p 3). Participants were instructed to 
take one capsule a day with water or another drink. 
The intervention started at day 0 (the day of screening, 
enrolment, and randomisation) and continued for 84 days 
or until delivery, whichever came first.
Procedures
At screening (day 0), qualified personnel recorded the 
participant’s medical history, did a medical examination, 
and collected a sample of venous blood (5–7 mL) for 
field measurement of haemoglobin (HemoCue Hb301 
analyser; HemoCue, Ängelholm, Sweden) and to do the 
malaria rapid test (Alere Bioline Malaria Ag Pf, Abbot, 
Seoul, South Korea). If a blood sample was positive for 
Plasmodium falciparum infection on the malaria rapid test, 
we followed up with microscopy to confirm the presence 
of P falciparum parasites. Blood samples were transferred 
on ice to the laboratory at MRCG@LSHTM Keneba 
fieldstation for a full blood count (Medonic M Series; 
Boule Diagnostics, Spånga, Sweden) and assessment of 
plasma hepcidin. Plasma hepcidin was assayed by an 
ELISA with a detection range of 0·049–25·0 µg/L 
(hepcidin-25 [human] EIA Kit; Peninsula Laboratories 
International, San Carlos, CA, USA). The assay was 
validated as part of a worldwide harmonisation exercise.23 
Hepcidin was quantified as single measurements to allow 
results within 24 h after blood collection and because of 
cost (appendix p 4). We also measured amounts in serum 
of ferritin, iron, unbound iron binding capacity, transferrin 
saturation, soluble transferrin receptor, C-reactive protein, 
and α1-acid glycoprotein, using an automated analyser 
(Cobas Integra 400 plus; Roche Diagnostics, Rotkreuz, 
Switzerland).
On day 2 and weekly thereafter, every participant 
was seen by a fieldworker who counted remaining 
supplements, measured axillary temperature, recorded 
self-reported side-effects, and gave the next week’s supply 
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of tablets. At day 14, day 49, and day 84, venous blood 
(5–7 mL) was gathered for assessments and processing, 
as described for day 0. At day 7 and weekly thereafter 
(except when venous blood was collected), field staff 
collected fingerprick capillary blood samples. At every 
timepoint, haemoglobin was measured by the HemoCue 
analyser, P falciparum infection was measured by the 
malaria rapid test, and hepcidin was assayed to ascertain 
subsequent allocation of iron or no iron in the two screen-
and-treat groups. To maintain masking of the treatment 
allocation, participants in the reference group also had 
weekly fingerprick blood samples collected and hepcidin 
concentrations analysed, even though the results did not 
affect subsequent supplement allocation.
At day 0, day 14, day 49, and day 84, we used freshly 
washed red blood cells for malaria growth assays. 
Remaining plasma was stored at –20°C for iron and 
bacterial growth assays. Day 14 was selected for the 
ex-vivo malaria susceptibility assays as a time when there 
would most likely be a high level of reticulocytosis. 
Day 49 was then selected as the midpoint between 
days 14 and endpoint at day 84. Reticulocyte counts 
were assessed by fluorescence-activated cell sorting of 
CD71-positive cells.
Gambian national guidelines stipulate that pregnant 
women should receive intermittent preventive treatment 
against malaria with sulfadoxine and pyrimethamine, 
beginning with the first dose at 16 weeks of gestation and 
then at least two other doses with an interval of 1 month 
between them. To ensure no interference with the 
malaria susceptibility assays, we arranged for participants 
to receive their first dose of sulfadoxine and pyri- 
methamine immediately after the blood sample was 
taken on day 49.
We measured ex-vivo growth rates of P falciparum 
parasites in fresh red blood cells and of four sen-
tinel bacterial species (Staphylococcus epidermidis, 
Staphylococcus aureus, Salmonella enterica, and Escherichia 
coli) in heat-inactivated serum as proxy safety indices, 
using methods described previously (appendix p 4).15,24 
The bacterial species were selected as frequent causes 
of sepsis in low-income settings and as representing a 
range of iron-acquisition mechanisms. Assays for 
S epidermidis proved unreliable, with frequent absence of 
any growth, so these findings have been excluded from 
the results. The technical reasons for this lack of growth 
were discovered in hindsight and insufficient samples 
were available to rerun the tests.
We monitored participants until delivery, and the 
outcomes of the pregnancy were registered for both 
mother and child (postnatal check-up within 72 h after 
delivery). When possible, reasons for a participant being 
lost to follow-up were recorded.
Outcomes
The primary outcome was the amount of haemoglobin at 
day 84, measured as the difference in haemoglobin in 
each screen-and-treat group compared with the reference 
group (WHO’s recommended regimen). Secondary out-
comes were the prevalence at day 84 of anaemia, iron 
deficiency, and iron-deficiency anaemia, the total iron 
dose administered over the 84-day study period, adverse 
events, and adherence to the assigned strategy.22
Anaemia was defined as an amount of haemoglobin 
less than 11 g/dL. Iron deficiency was defined as a con-
centration in plasma of ferritin lower than 15 µg/L if 
C-reactive protein was lower than 5 mg/L, or plasma 
ferritin lower than 30 µg/L if C-reactive protein was 
higher than 5 mg/L. Iron-deficiency anaemia was defined 
as an amount of haemoglobin lower than 11 g/dL and 
plasma ferritin less than 15 µg/L when C-reactive protein 
was less than 5 mg/L, or haemoglobin lower than 11 g/dL 
and plasma ferritin less than 30 µg/L when C-reactive 
protein was higher than 5 mg/L and the ferritin index 
[soluble transferrin receptor:log10-ferritin] was greater 
than 2·0). Adverse events were defined as any untoward 
or unfavourable medical occurrence, including signs 
and symptoms associated temporally with the research 
procedure or trial intervention, whether considered 
related to the woman’s participation in the research or 
not. Serious adverse events were investigated by a doctor 
and defined as any adverse event that was life-threatening 
or resulted in death or required admission to hospital or 
prolongation of admission, was a persistent or relevant 
disability or incapacity, was a congenital anomaly or birth 
defect, or was a reported maternal death, miscarriage, or 
stillbirth. Adherence was calculated as described in the 
appendix (p 5).
Statistical analysis
For our sample size calculation, we used data from a 
previous study in neighbouring villages25 to analyse 
haemoglobin concentrations, which yielded an SD of 
12·8 g/L. This value was used to calculate a sample size 
of 154 participants for each of the three arms, using a 
one-sided α of 2·5% with a conservative Bonferroni-type 
correction. Initially, a total sample size of 462 pregnant 
women was calculated, assuming less than 10% loss to 
follow-up. With a non-inferiority margin of –5·0 g/L, this 
number was used to provide 80% power to establish that 
the 60 mg screen-and-treat approach is non-inferior to 
WHO’s recommended regimen, the 30 mg screen-and-
treat approach is non-inferior to WHO’s recommended 
regimen, and the 30 mg screen-and-treat approach is 
non-inferior to the 60 mg screen-and-treat approach. To 
ensure that the study was done across different seasons 
and to ensure that detailed monitoring could be achieved, 
we enrolled study participants in six cohorts starting 
from June, 2014, then roughly every 3–4 months after-
wards, from September, 2014, January, 2015, April, 2015, 
August, 2015, and December, 2015. After the first two 
cohorts were enrolled, permission was obtained from the 
ethics committee to increase the sample size to 498, 
because loss to follow-up exceeded 10%.
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Per-protocol analysis was used to assess non-inferiority 
of the primary outcome. All missing values and outliers 
present after data lock (on March 13, 2017) were main-
tained. In the intention-to-treat analysis, missing values 
were replaced by multiple imputation (appendix p 5). 
Intervention effects on continuous variables were mea-
sured as the difference in mean estimates, with logarithmic 
transformation (ln) as appropriate. A modi fied intention-
to-treat analysis was also done (excluding participants 
withdrawn before the first dose of iron supplementation), 
and groups were compared using linear regression 
analysis, with intervention entered as a dummy-coded 
categorical variable. For analyses of bacterial growth, 
differences between timepoints were assessed by repeat 
measures ANOVA and Scheffé’s post-hoc tests. Differences 
between study groups were assessed by χ² test.
The number of adverse events was too low to allow 
meaningful analysis by type of adverse event. For 
every woman, we summed the counts for various types 
of adverse events. We used negative binomial reg-
ression to assess group differences in observed counts. 
Negative binomial regression was used instead of 
Poisson regression to account for overdispersion (ie, 
where the variance exceeds the mean). Effect sizes thus 
obtained are reported as the relative change in observed 
counts. Adherence was assessed as the extent to which 
the participant’s history of supplementation coin-
cided with the prescribed supplementation (appendix 
pp 5–7).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all 
data in the study and had final responsibility for the 
decision to submit for publication.
Figure 1: Trial profile
RDT=rapid diagnostic test.
498 were randomly assigned
527 gave informed consent
683 pregnant women were screened for the study
167 were allocated to the reference group 
(WHO’s recommended 60 mg regimen)
1 was excluded (no supplement given) 2 were excluded (no supplement given)
166 were allocated to the 60 mg 
screen-and-treat approach
29 were excluded
      27 did not attend on recruitment day
         1 was RDT-positive 
         1 gestational age was out of range
26 were lost to follow-up
7 withdrew consent
2 missed too many visits
5 had adverse events or serious 
adverse events
12 delivered during study
31 were lost to follow-up
5 travelled away
5 withdrew consent
2 missed too many visits
5 had adverse events or serious 
adverse events
13 delivered during study
1 unknown reason
18 were lost to follow-up
1 travelled away
4 withdrew consent
1 missed  too many visits
1 had adverse events or serious 
adverse events
10 delivered during study
1 unknown reason
165 were allocated to the 30 mg 
screen-and-treat approach
166 were included in the modified 
intention-to-treat analysis
164 were included in the modified 
intention-to-treat analysis
165 were included in the modified 
intention-to-treat analysis
140 completed the 12-week intervention 
period and were included in the 
per-protocol analysis
133 completed the 12-week intervention 
period and were included in the 
per-protocol analysis
147 completed the 12-week intervention 
period and were included in the 
per-protocol analysis
156 did not give consent
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Results
Between June 16, 2014, and March 3, 2016, we identified 
683 pregnant women with a gestational age of 
14–22 weeks, of whom 527 consented to take part in the 
trial. Of these pregnant women, 29 were excluded, 
mainly because they did not attend on recruitment day 
(figure 1). Six cohorts were enrolled, with 51 women 
enrolled from June, 2014, then 87 from September, 2014, 
99 from January, 2015, 75 from April, 2015, 96 from 
August, 2015, and 90 from December, 2015. Of these 
498 participants who were enrolled, 167 were allocated 
to WHO’s recommended regimen (the reference 
group), 166 were allocated to the 60 mg screen-and-treat 
approach, and 165 were allocated to the 30 mg screen-
and-treat approach. Among these 498 participants, 
78 (16%) were withdrawn or lost to follow up before the 
scheduled completion of the intervention, with no 
evidence of a marked imbalance in non-completion 
between groups (figure 1). The per-protocol population 
therefore included 420 women, of whom 140 were 
assigned to WHO’s recommended regimen, 133 were 
allocated to the 60 mg screen-and-treat approach, and 
147 were allocated to the 30 mg screen-and-treat ap-
proach. Three participants were excluded before the first 
supplement was received, resulting in 495 women being 
included in the modified intention-to-treat analysis.
Participants’ characteristics at enrolment were similar 
between study groups (appendix pp 8–11) and indicated a 
population with high prevalence of anaemia (>50%). 
A third of all women were iron-deficient using ferritin 
thresholds adjusted for inflammation. Poor iron status 
in the study population was confirmed by the high 
prevalence of other iron markers with abnormal values. 
About a third of participants had inflammation, as 
measured by C-reactive protein and α1-acid glycoprotein. 
Sickle-cell disorder was absent. Only one participant had 
a positive test for P falciparum infection.
In the per-protocol analysis, the difference in haemo- 
globin at day 84 did not exceed the preset non-inferiority 
margin of –5 g/L in the two screen-and-treat groups when 
compared with the reference group (table 1; figure 2). 
Moreover, the 30 mg screen-and-treat approach did not 
differ substantively from the 60 mg screen-and-treat 
approach (figure 2). Findings were similar in the modified 
intention-to-treat analysis (vs the reference group [n=166], 
–1·3 g/L, 95% CI –3·5 to 1·0 with the 60 mg screen-
and-treat approach [n=164], and –2·9 g/L, –5·1 to –0·7 with 
the 30 mg screen-and-treat approach [n=165]).
Compared with the reference group, hepcidin, ferritin, 
and the ferritin index (measures of iron deficiency) 
were all significantly lower at day 84 in both screen-and-
treat groups (table 1). Values for other iron markers 
(eg, serum iron, transferrin, soluble transferrin receptor, 
and unbound iron binding capacity) confirmed these 
results (appendix pp 12–16). The prevalence of anaemia 
and iron deficiency showed a similar picture, although 
the contrasts between groups were more striking 
(table 2). In the reference group, the prevalence of 
anaemia dropped from 58% at day 0 to 45% at day 84 but 
rose in the two screen-and-treat groups, from 52% at 
day 0 to 57% at day 84 with the 60 mg screen-and-treat 
approach, and from 53% at day 0 to 59% at day 84 
with the 30 mg screen-and-treat approach, such that 
the two screen-and-treat approaches were clearly 
inferior to WHO’s recommended regimen. The preva-
lence of being ready-and-safe to receive iron declined 
substantially in the reference group, from 56% at 
day 0 to 21% at day 84, which was a lower prevalence at 
day 84 than in both screen-and-treat groups (42% in the 
Figure 2: Non-inferiority tests
Per-protocol analysis of change in haemoglobin from day 0 to day 84. Values are 
mean difference (95% CI). Dotted line shows the preset non-inferiority 
margin of –5 g/L.
–10 –5 0 5 10
60 mg screen-and-treat
approach vs reference
30 mg screen-and-treat
approach vs reference
30 mg vs 60 mg
screen-and-treat approach
–2·2 (–4·6 to 0·1)
–2·7 (–5·0 to –0·5)
–0·5 (–2·8 to 1·8)
Haemoglobin (g/L)
Mean difference
(95% CI)
Participants with 
data available (n)
Mean estimate 
(SE or GSD)
Effect (95% CI)
Haemoglobin at day 84 (g/L)*
Reference group 139 110·1 (0·8) ··
60 mg screen-and-treat approach 131 107·9 (0·8) –2·2 (–4·6 to 0·1)
30 mg screen-and-treat approach 145 107·4 (0·8) –2·7 (–5·0 to –0·5)
Hepcidin at day 84 (µg/L)†‡
Reference group 140 6·3 (3·4) ··
60 mg screen-and-treat approach 132 3·3 (4·2) 0·52 (0·37 to 0·75)
30 mg screen-and-treat approach 147 2·3 (4·7) 0·37 (0·26 to 0·52)
Ferritin at day 84 (µg/L)†
Reference group 139 34·6 (1·9) ··
60 mg screen-and-treat approach 130 23·1 (1·8) 0·67 (0·58 to 0·77)
30 mg screen-and-treat approach 145 21·4 (1·7) 0·62 (0·54 to 0·71)
Ferritin, inflammation-adjusted, at day 84 (µg/L)†
Reference group 139 31·6 (0·1) ··
60 mg screen-and-treat approach 130 21·2 (0·1) 0·67 (0·58 to 0·77)
30 mg screen-and-treat approach 145 19·3 (0·1) 0·61 (0·53 to 0·70)
Ferritin index at day 84†§
Reference group 139 2·2 (1·5) ··
60 mg screen-and-treat approach 129 2·9 (1·5) 1·35 (1·23 to 1·49)
30 mg screen-and-treat approach 145 3·1 (1·5) 1·43 (1·31 to 1·58)
Logarithmic transformation (ln) was done for hepcidin and ferritin variables. GSD=geometric SD. *Estimates are 
mean (SE); SE obtained by the Delta method. Effect is absolute difference in mean estimate versus the reference group. 
†Estimates are geometric mean (GSD). Exponentiation of ln-transformed variables yielded effects expressed as ratios 
of geometric mean estimates versus the reference group. ‡Estimates obtained using Tobit regression on 
ln-transformed hepcidin concentrations were left-censored at 0·049 µg/L (limit of detection) and right-censored at 
25 µg/L. §Ferritin index is the ratio soluble transferrin receptor: log10-ferritin. 
Table 1: Primary and secondary outcomes, continuous variables
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60 mg screen-and-treat group and 52% in the 30 mg 
screen-and-treat group), indicating better iron status in 
the reference group (appendix p 23). The prevalence of 
iron-deficiency anaemia showed a greater decline in the 
reference group (39% at day 0 to 17% at day 84) than in 
the 60 mg screen-and-treat group (from 40% to 29%), 
and in the 30 mg screen-and-treat group the prevalence 
increased slightly (from 37% to 40%). Iron deficiency 
prevalence defined using a soluble transferrin receptor 
threshold of greater than 4·4 mg/L showed a very 
similar pattern, with the prevalence of iron-deficiency 
anaemia also higher in both screen-and-treat groups at 
day 84 (appendix pp 17–19).
Adherence to daily supplementation was 86% in all 
study groups and was similar between groups (table 2). 
Participants in the 60 mg and 30 mg screen-and-treat 
groups received, respectively, 46% and 53% of the 
number of supplemental iron doses received by their 
peers in the reference group.
The frequency of adverse events and serious adverse 
events was similar between study groups (table 3). The 
frequency of self-reported illnesses and side-effects 
(ie, black stool, constipation, dizziness, fatigue, nausea, 
and stomach ache) was similar in the 60 mg screen-and-
treat group (14%) and in the reference group (11%; 
difference 2·5%, 95% CI 0·3 to 4·8); in the 30 mg screen-
and-treat group the frequency was lower than in the 
reference group (8%; difference –3·5%, 95% CI –5·4 to 
–1·6). The most frequent side-effect was stomachache, 
which was similar in the 60 mg screen-and-treat group 
(82 cases per 1906 person-weeks) and in the reference 
group (81 cases per 1974 person-weeks; effect 1·0, 95% CI 
0·7 to 1·6); in the 30 mg screen-and-treat group the 
frequency of stomachache was slightly lower than in 
the reference group (58 cases per 2009 person-weeks; 
effect 0·7, 95% CI 0·5 to 1·1; appendix pp 20–22). No 
participants died during the study. 
The growth of malaria parasites in fresh red blood cells 
was suppressed at day 0 (compared with non-anaemic 
controls), was greatly stimulated at day 14, and had 
gradually declined to day 0 levels by day 84, with no 
differences between study groups at any timepoint 
(figure 3A). Compared with day 0, before iron sup-
plementation began, ex-vivo growth of E coli, S enterica, 
and S aureus was significantly faster at day 14, day 49, and 
day 84 (figure 3B). On day 14 and day 49, no differences 
were noted between study groups. On day 84, serum 
samples from women in the reference group supported 
faster bacterial growth of E coli and S aureus compared 
with women in the 30 mg screen-and-treat group, and 
E coli growth was faster at day 84 in the reference group 
compared with the 60 mg screen-and-treat group. This 
effect was attributable to the acute effect of iron 
administered to women in the 60 mg and 30 mg screen-
and-treat groups, who had amounts of hepcidin measured 
7 days previously below the 2·5 µg/L threshold. The 
appendix (p 24) shows no difference in bacterial growth 
across study groups among women who received iron 3 h 
before the blood draw and significantly lower growth in 
those in the 60 mg and 30 mg screen-and-treat groups 
who did not have iron.
Number of 
participants/total with 
data available (n/N)
Prevalence (%) Effect (95% CI)
Anaemia at day 84 (haemoglobin <110 g/L)
Reference group 63/139 45% ··
60 mg screen-and-treat approach 75/131 57% 11·9 (0·1 to 23·8)
30 mg screen-and-treat approach 86/145 59% 14·0 (2·5 to 25·5)
Ready-and-safe to receive iron at day 84 (hepcidin <2·5 µg/L)
Reference group 30/140 21% ··
60 mg screen-and-treat approach 55/132 42% 20·2 (9·4 to 31·1)
30 mg screen-and-treat approach 77/147 52% 31·0 (20·4 to 41·5)
Ferritin index >2·0 at day 84
Reference group 82/140 59% ··
60 mg screen-and-treat approach 116/133 87% 28·6 (18·7 to 38·6)
30 mg screen-and-treat approach 131/147 89% 30·5 (21·0 to 40·1)
Iron-deficiency anaemia at day 84
Reference group 24/140 17% ··
60 mg screen-and-treat approach 38/131 29% 11·9 (1·9 to 21·8)
30 mg screen-and-treat approach 58/146 40% 22·6 (12·5 to 32·7)
Iron dosage (% of weeks in which iron was received)
Reference group 1974/1974* 100% ··
60 mg screen-and-treat approach 1025/1905* 46% –53·8 (–56·0 to –51·6)
30 mg screen-and-treat approach 952/2009* 53% –47·4 (–49·6 to –45·2)
Adherence
Reference group 275/1974* 86% ··
60 mg screen-and-treat approach 260/1905* 86% 0·3 (0·3 to 0·3)
30 mg screen-and-treat approach 246/2009* 86% 1·7 (1·7 to 1·7)
*Data are cases/person-weeks.
Table 2: Secondary outcomes, categorical variables
Cases/
person-weeks
Observed number of events Effect (95% CI)
Reported side-effects (aggregate score)
Reference group 220/1974 111 per 1000 person-weeks ··
60 mg screen-and-treat approach 261/1906 135 per 1000 person-weeks 1·2 (0·8 to 1·8)
30 mg screen-and-treat approach 154/2009 78 per 1000 person-weeks 0·7 (0·5 to 1·0)
Adverse events
Reference group 167/1902 89 per 1000 person-weeks ··
60 mg screen-and-treat approach 149/1861 82 per 1000 person-weeks –7·4 (–26·0 to 11·1)
30 mg screen-and-treat approach 175/1945 89 per 1000 person-weeks 1·6 (–17·2 to 20·3)
Serious adverse events (DSMB notified)
Reference group 9/1904 29 per 10 000 person-weeks ··
60 mg screen-and-treat approach 14/1861 47 per 10 000 person-weeks 18·7 (–12·3 to 49·8)
30 mg screen-and-treat approach 6/1945 18 per 10 000 person-weeks –10·2 (–34·0 to 13·6)
Individual complaints and adverse events are listed in the appendix (pp 20–22). Estimates of adverse events and 
serious adverse events were based on a negative binomial model, accounting for differences in exposure. The effect 
and 95% CI are the respective exponentiated relative changes in observed counts and their CIs. DSMB=data safety 
monitoring board.
Table 3: Safety outcomes
Articles
e1571 www.thelancet.com/lancetgh   Vol 7   November 2019
Discussion
The findings of our study show that iron exposure was 
reduced by half in the 60 mg screen-and-treat group 
(46% as much iron) and reduced by three-quarters in the 
30 mg screen-and-treat group (27% as much iron). The 
screen-and-treat approaches were both non-inferior to 
WHO’s recom mended 60 mg daily regimen, with respect 
to the primary outcome of difference in amount of 
Figure 3: Ex-vivo assays of malaria growth in erythrocytes and sentinel bacteria growth in serum
Left panel in (A) shows growth rates of Plasmodium falciparum strain FCR3-FMG in fresh RBCs relative to growth in RBCs from non-anaemic controls. Right panel 
in (A) shows reticulocyte counts relative to non-anaemic controls. Black lines show mean values and error bars show SEs. Compared with day 0, parasite growth and 
reticulocyte counts were significantly higher at day 14 (p=0·0012) and day 49 (p=0·0014), with no differences between treatment groups. Upper section in (B) shows 
individual participant data. Black lines show mean values and error bars show SEs. Compared with day 0, faster growth rates were seen on day 14, day 49, and day 84, 
for all species (p<0·0001 for all times). Lower plots in (B) show the proportion of serum samples from participants in which ex-vivo growth rates were greater than 
the 95% percentile, calculated on day 0 across all groups. All organisms showed significant increases after iron supplementation (p=0·0090). No differences between 
study groups were noted. RBC=red blood cell. *p<0·0001. †p<0·0001. ‡p=0·0011.
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haemoglobin at day 84, according to our definition, with 
the lower limit of the confidence intervals falling within 
the preset non-inferiority margin. However, all secondary 
outcome measures of iron status showed evidence of 
inferiority. The prevalence of anaemia declined with the 
WHO recommended regimen but increased in both 
screen-and-treat groups. Likewise, the prevalence of 
iron deficiency and iron-deficiency anaemia was higher 
in both screen-and-treat groups compared with the 
reference group. Even the reference group had low 
apparent efficacy, with a 3·3 g/L improvement in 
haemoglobin over the 84-day study period and only a 
13% reduction in anaemia, despite being implemented 
under the ideal conditions of an efficacy trial. However, 
true efficacy in ameliorating the haemodilution of 
pregnancy cannot be judged in the absence of a placebo 
arm.
Iron is a problematic nutrient with both beneficial and 
potentially harmful effects. Some of these effects can be 
serious, particularly in low-income settings where 
infections are common.26 Detection of differences in 
prevalence of serious infections would need a very large 
trial and, in the case of malaria, would be unethical 
because intermittent preventive treatment for pregnant 
women is advised, and in The Gambia it is mandated. 
We also issued insecticide-treated bed nets to all 
participants at enrolment. In view of these constraints, 
we used proxy assays of likely infection potential for 
malaria and for three sentinel bacteria that use a range of 
iron-acquisition mechanisms. By doing these ex-vivo 
assays at day 0, on day 14 and day 49 we were able to 
capture short-term and medium-term effects of chronic 
iron administration. On day 84, blood was drawn 3 h after 
the last oral iron (or non-iron) supplement and, hence, 
results at day 84 capture both chronic and acute post-
absorptive effects of iron. Malaria parasite assays have 
previously provided a robust mechanism to account for 
how iron-deficiency anaemia protects against P falciparum 
infection (parasite invasion and growth rates are poor in 
older microcytic red blood cells) and why supplementation 
abrogates this effect (parasite invasion and growth rates 
are high in reticulocytes and large young red blood 
cells).15,27,28 These effects are replicated in our study and 
concur with associated changes in CD71 (a reticulocyte 
marker). No difference in plasmodial growth was noted 
between treatment groups at any timepoint, possibly 
because the most iron-deficient participants in all 
groups received iron early in the trial, which elicited a 
broadly similar reticulocyte surge despite the poorer 
overall performance of the two screen-and-treat groups. 
Reticulocytosis is also a natural response to the expansion 
of blood volume in mid-pregnancy and might have 
contributed to the increased risk of infections.29 Note that 
the absence of an acute effect of iron administration at 
day 84 is entirely consistent with the fact that the assay 
uses washed red blood cells and their susceptibility is 
governed by cell morphology rather than iron content.24
Growth rates of all three bacteria rose strikingly in 
all treatment groups after commencement of iron 
supplementation. In the absence of a placebo group, we 
cannot conclude that this increase is an effect of iron 
(or other micronutrients), but it seems highly likely. 
Pregnancy-related changes in humoral immunity are an 
unlikely explanation since plasma was heat-inactivated 
before inoculation. Furthermore, the growth-stimulatory 
effect of iron is clearly shown by the response to the 
acute iron and micronutrient administration 3 h before 
the blood draw on day 84. This finding corroborates 
our previous results in adult men, in whom bacterial 
growth rates were promoted by previous iron (without 
additional micronutrients) and were highly correlated 
with amounts in serum of iron and transferrin 
saturation.24 These ex-vivo assays might not equate to 
the situation in vivo but are highly suggestive that 
bloodstream bacteria would grow faster at higher 
concentrations of iron and transferrin saturation and 
would, therefore, have a greater chance of overcoming 
immune defences.
The real or perceived side-effects of taking oral iron 
supplements are less serious than the threat of a major 
infection, but they are important insofar as they lead 
to poor adherence to iron supplementation. The lesser 
performance of the two screen-and-treat groups in 
resolving iron deficiency and iron-deficiency anaemia 
might have been acceptable if evidence showed that they 
were safer or had fewer side-effects, as we initially 
postulated. In fact, the prevalence of self-reported illnesses 
and side-effects was highest in the 60 mg screen-and-
treat group, possibly because women in the reference 
group adapted to iron supplementation better than when 
administration was intermittent (with on and off weeks). 
As might be expected, the prevalence of illnesses and side-
effects was lowest in the 30 mg screen-and-treat group. 
Note that the unusually high adherence in this study could 
reflect the influence of sensitisation and fieldworker 
encouragement and the fact that participants were aware 
that adherence was being monitored.
There are several possibilities why the screen-and-treat 
approach did not work as we expected. First, it is possible 
that weekly screening does not adequately capture the 
short-term dynamics of hepcidin’s responses to recent 
iron intake30,31 or intercurrent infections and inflammation 
and that more frequent screening is needed. Even if this 
were the case, and a point-of-care test were available, it 
would be entirely impractical to screen more frequently. 
A second possibility is that our hepcidin threshold, 
calculated to diagnose iron deficiency,19 did not adequately 
differentiate iron absorbers from iron blockers (because 
the derivation did not include information on iron 
absorption). A higher threshold might have yielded more 
frequent dosing and a higher efficacy but would have 
been less effective at reducing the total number of women 
given iron, and it should not have been necessary because 
we already prioritised sensitivity over specificity in 
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selecting the threshold (appendix pp 1, 2). A lower 
threshold would have reduced efficacy yet further. Our 
surmise is that the large bolus doses of highly absorbable 
ferrous fumarate override the physiological mechanism 
of hepcidin-induced iron blockade evolved to regulate 
duodenal iron absorption from foods and, hence, iron 
continued to be absorbed in the reference group even in 
the face of raised hepcidin.
Our study had several strengths and some weaknesses. 
Hepcidin is theoretically the ideal index of ready-and-safe 
to receive iron and it very effectively reduced the amount 
of iron administered in an area with high anaemia 
prevalence. The study had adequate statistical precision 
for the main outcomes, was done to Good Clinical 
Practice standards, and had high adherence and relatively 
few dropouts. One limitation is that the sample size was 
insufficient to capture potentially rare adverse events, 
and another is that the trial was conducted in an area 
with low malaria transmission, high use of insecticide-
treated bed nets, and intermittent preventive treatment 
for pregnant women and, hence, could not assess to what 
extent the screen-and-treat approach reduced the risk of 
malaria. Our proxy safety outcomes for malarial and 
bacterial infections provide intuitively solid outcomes 
but might not reflect in-vivo susceptibility. Provision of 
iron with multiple other micronutrients can be viewed as 
both a strength and a weakness: a strength because 
other nutrient deficiencies that might limit the 
acquisition or utilisation of iron should be eradicated, 
and a weakness because of possible nutrient–nutrient 
interactions (eg, zinc in UNIMMAP might compete with 
iron for absorption). Note also that UNIMMAP capsules 
are not enteric-coated, which will not affect aggregate 
iron availability but may cause loss of other micro- 
nutrients. Because all participants received the same 
UNIMMAP, except for differences in iron content, this 
concern would not affect comparison between study 
groups.
Previous evidence shows that intermittent iron supple-
mentation in pregnancy is somewhat less efficacious 
than daily supplementation,4,11 and we conclude from this 
study that a hepcidin-guided screen-and-treat strategy 
does not overcome this limitation. Our results are likely 
to be generalisable at least to other populations in LMICs 
with high prevalence of anaemia and iron deficiency and 
in a low malaria setting. Future alternatives to universal 
oral iron supplementation in pregnancy might include 
use of parenteral iron formulations such as ferric 
carboxymaltose, which can deliver up to 1000 mg 
elemental iron over a 15-min infusion. This approach 
will need evidence of cost-effectiveness and safety in 
low-income settings, together with development of 
infrastructure, to overcome barriers to implementation. 
Therefore, we support continued application of the 
current WHO guidelines but urge development of novel 
iron formulations with much better side-effect profiles to 
encourage improved adherence. The findings of our 
malaria susceptibility assays underscore the importance 
of the WHO guide line that iron administration in 
malarious areas should ideally be implemented in 
conjunction with adequate measures to prevent, 
diagnose, and treat malaria.32
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